https://www.ajmc.com/view/dr-rajat-bannerji-discusses-captivate-findings-of-ibrutinib-venetoclax-fixed-duration-treatment-in-cll
Rajat Bannerji, MD, PhD, Chief, Section of Hematologic Malignancies at Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, speaks on the efficacy and...
drrajatbannerjidiscussescaptivate